Complexity Has Benefits: Data Show Biologics, Targeted Agents Have Better Approval Prospects
Executive Summary
Biologics have 9.1% likelihood of making it through the clinic to approval, compared to 5.7% for new molecular entities, according to an analysis of 10 years of Biomedtracker drug development data by BIO, Informa Pharma Intelligence and QLS.